umeclidinium and vilanterol by the end of the year in COPD. The combination is an inhaled corticosteroid, long acting muscarinic antagonist and a long-acting beta agonist. It met its co-primary ...

AstraZeneca may mount a challenge to GlaxoSmithKline’s three-in-one inhaler for chronic obstructive pulmonary disease (COPD ... as well as PT009 – a combination of budesonide formoterol ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

DOI: 10.1136/bmj-2024-080409 Meng-Ting Wang et al, Environmentally friendly inhaler regimens for COPD, BMJ (2024). DOI: 10.1136/bmj.q2825 ...

The Toward a Revolution in COPD Health (TORCH ... and fluticasone propiniate, an inhaled cortical steroid, either alone or in combination, on mortality, exacerbations, health-related quality ...

A further 500 were given the triple combination but in two inhalers. COPD is term used to describe a number of progressive lung diseases such as emphysema. The main cause is smoking, although the ...

Eligible patients had COPD, were ages 40 or older ... study inhaler or an inhaled corticosteroid-LAMA-LABA combination via separate inhalers. The cohort included 87,751 individuals, from which ...

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

“We are proud to continue advancing our asthma and COPD inhaled drug program, achieving key clinical development milestones on schedule,” said Xian-Ming Zeng, Ph.D., CEO of Transpire Bio.

For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.